Human CD197/CCR7 (CAP-100) Antibody is a research-grade biosimilar monoclonal antibody. It is a human IgG antibody. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.
C-C chemokine receptor type 7 (CD197/CCR7) is a ~42 kDa protein. Receptor for the MIP-3-beta chemokine. Probable mediator of EBV effects on B-lymphocytes or of normal lymphocyte functions.
Product Name:
Human CD197/CCR7 (CAP-100) Antibody
SKU:
GXBS00980
Size:
100 µg, 1 mg
Antibody Type:
Monoclonal Antibody
Clone:
CAP-100
Target:
CDw197
Isotype:
IgG
Host Species:
Human
Reactivity:
Human
Applications:
ELISA, FACS, Functional assay, Research in vivo
Expression Host:
Mammalian cells
Synonyms:
CAP-100, CAP100, CAP100
Biological Activity:
CAP-100 (0.1-10 ng/uL) demonstrates the most potent binding to CCR7 immunogen SYM1899 (100 ng) with a EC 50 of 1.78 ng/mL [1]. CAP-100 (0.01-100 ug/mL) shows dose-dependent inhibition of ligand-induced activation, reaching maximal inhibitions close to 100% in CCR7 + CHO-K1 cells stimulated with CCL19 [1]. CAP-100 (0.1-100 ug/mL) binds to CCR7 + non-tumor PB or BM cells from healthy donors at high experimental concentrations [1]. CAP-100 (1-100 ug/mL) impairs the increase of D-actin upon CCL19/CCL21 stimulation in CLL cells [1]. CAP-100 (0.1-100 ug/mL, 4 h) demonstrates a strong dose-related inhibitory activity against CCR7-driven T-PLL cells migration towards 1 ug/mL of CCL19 or CCL21 [1]. CAP-100 (10 ug/mL) impairs CCR7-induced migration of CCL cells in trans-endothelial migration (TEM) assays [1]. CAP-100 (10-100 ug/mL, 24 h) does not mediate direct specific-induced cell death but impairs the viability of CCR7-mediated cells which is the protective function in CLL [1]. CAP-100 (10 ug/mL) activated human NK-92-CD16 + cells to induce a strong ADCC on target CLL cells [1]. CAP-100 (10 ug/mL, i.v., one single dose) reduces in vivo homing of CCR7-expressing cells to lymph node of NSG mice [1]. CAP-100 (25-200 ug/mouse, i.v., one single dose) shows prolonged median overall survival regardless of dose and reduces tumor burden as well as reducing lymph node infiltration in Granta-519-luc + -bearing mice [1]. CAP-100 (10-200 ug/mouse, i.v., one single dose) significantly extends the lifespan of JVM-3-bearing SCID mice compared to Trastuzumab () (200 ug) [1].
Purity:
>95% purity as determined by SDS-PAGE.
Endotoxin Level:
< 10 EU/mg
Formulation:
0.01M PBS pH 7.4
State of Matter:
Liquid
Regulatory Status:
For research use only. Not suitable for clinical or therapeutic use.
Product Preparation:
Protein A/G purified from cell culture supernatant.
Storage and Handling:
Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
![APC Anti-Human CD197/CCR7 Antibody [G043H7] (AGEL1804)](https://cdn11.bigcommerce.com/s-h68l9z2lnx/images/stencil/590x590/products/22335/605919/apc-anti-human-cd197ccr7-antibody-g043h7-agel1804__68148.1707496388.jpg?c=2 "APC Anti-Human CD197/CCR7 Antibody [G043H7] (AGEL1804)")
![FITC Anti-Human CD197/CCR7 Antibody [G043H7] (AGEL1802)](https://cdn11.bigcommerce.com/s-h68l9z2lnx/images/stencil/590x590/products/22333/606698/fitc-anti-human-cd197ccr7-antibody-g043h7-agel1802__13212.1707498802.jpg?c=2 "FITC Anti-Human CD197/CCR7 Antibody [G043H7] (AGEL1802)")
![GenieFluor 488 Anti-Human CD197/CCR7 Antibody [G043H7] (AGEL1809)](https://cdn11.bigcommerce.com/s-h68l9z2lnx/images/stencil/590x590/products/22340/606499/geniefluor-488-anti-human-cd197ccr7-antibody-g043h7-agel1809__02329.1707498199.jpg?c=2 "GenieFluor 488 Anti-Human CD197/CCR7 Antibody [G043H7] (AGEL1809)")
![PE Anti-Human CD197/CCR7 Antibody [G043H7] (AGEL1803)](https://cdn11.bigcommerce.com/s-h68l9z2lnx/images/stencil/590x590/products/237578/618354/pe-anti-human-cd197ccr7-antibody-g043h7-agel1803__75767.1732238724.jpg?c=2 "PE Anti-Human CD197/CCR7 Antibody [G043H7] (AGEL1803)")